April 27th, Monday.


Today, two healthcare stocks in Hong Kong IPOed, with a clear divergence: Tianxing Healthcare vs. Kefu Healthcare.
Tianxing Healthcare: First Hong Kong IPO, after failing to list on the A-share Sci-Tech Innovation Board, shifted to Hong Kong. Currently oversubscribed by over 280 times, small cap + medical devices + good profitability, sentiment is positive. I bought some cash as a lottery participation, whether it hits or not is up to fate.
Kefu Healthcare: Listed on the A-share market in 2021, this is a secondary financing in Hong Kong. The current A-share price is about 54 yuan, with a Hong Kong listing price of 39 HKD, which is a discounted issuance, but essentially anchored to the A-share price, locking in the price range. Plus, oversubscription is only 2.8 times, with very low enthusiasm, so this kind of stock doesn’t tie up capital.
My feeling is: Tianxing “betting on winning the lottery for high odds”; Kefu “even winning the lottery is hard to make money.”
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin